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Despite more than sixty years of clinical trials, tuberculosis (TB) still causes a high global burden of 3 
mortality and morbidity.  Treatment currently requires multiple drugs in combination, taken over a 4 
prolonged period.  New drugs are needed to shorten treatment duration, prevent resistance and reduce 5 
adverse events.  However, to improve on current methodology in drug development, a more complete 6 
understanding of the existing clinical evidence base is required. 7 
 8 
Methods 9 
A systematic review was undertaken to summarise outcomes reported in Phase III trials of patients 10 
with newly-diagnosed pulmonary TB.  A systematic search of databases (PubMed, MEDLINE, 11 
EMBASE, CENTRAL and LILACs) was conducted on 30th November 2017 to retrieve relevant peer 12 
reviewed articles. Reference lists of included studies were also searched. This systematic review 13 
considered all reported outcomes. 14 
 15 
Results 16 
Of 248 included studies 229 considered “on-treatment” outcomes whilst 148 reported “off-treatment” 17 
outcomes.  There was wide variation and ambiguity in the definition of reported outcomes, including 18 
their relationship to treatment and in the time points evaluated.  Additional challenges were observed 19 
regarding the analysis approach taken (per protocol versus intention to treat) and the varying durations 20 
of “intensive” and “continuation” phases of treatment. Bacteriological outcomes were most frequently 21 
reported but radiological and clinical data were often included as an implicit or explicit component of 22 
the overall definition of outcome. 23 
 24 
Conclusions  25 
Terminology used to define long-term outcomes in phase III trials is inconsistent, reflecting evolving 26 
differences in protocols and practices.  For successful future cumulative meta-analysis, the findings of 27 
3 
 
this review suggest that greater availability of individual patient data and the development of a core 1 
outcome set would be desirable. In the meantime we propose a simple and logical approach which 2 
should facilitate combination of key evidence and inform improvements in the methodology of TB 3 
drug development and clinical trials. 4 
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Tuberculosis (TB) remains a major killer amongst infectious diseases with 10.4 million new cases and 2 
1.8 million deaths worldwide in 2015.[1]  Though TB incidence has fallen by an average of 1.5% per 3 
year since 2000,  this needs to accelerate to a 4-5% annual decline to reach the 2020 milestones of the 4 
World Health Organisation’s End TB Strategy which include reducing TB deaths by 90% and cutting 5 
new cases by 80% between 2015 and 2030.[2]  Ending the TB epidemic by 2030 is also among the 6 
health targets of the newly adopted Sustainable Development Goals.[3] 7 
Current treatment for drug-sensitive tuberculosis, involves administration of four drugs for six 8 
months, while for multi-drug resistant disease, up to seven drugs for nine to twenty-four months may 9 
be required.  New drugs and regimens are required to shorten treatment duration, reduce toxicity and 10 
combat drug resistance but the optimal critical path for novel regimens is not well-defined. Currently, 11 
clinical development of a single novel TB drug is expected to take not less than six years, while a 12 
completely novel combination regimen developed sequentially would require around twenty years or 13 
more.[4]  Phase III trials aiming to shorten the duration of first-line TB therapy must be large and 14 
follow-up prolonged because of the strength of the current comparator in assuring stable cure.[5]  15 
Recent such trials have been costly and global capacity for supporting them is limited.[6] 16 
Possible outcomes for phase III TB trials have a number of important dimensions.  Studies may focus 17 
on bacteriological, clinical and/or radiological outcomes, or some combination of the three and these 18 
outcomes are typically followed on multiple occasions during and after treatment. The structure of 19 
treatment regimens has varied historically with de-intensification after an initial “intensive” phase a 20 
common feature and the necessary duration of follow-up post-treatment has not been defined.  21 
Investigators commonly report apparently simple outcomes such as cure, relapse and death which 22 
may have very different meanings in different studies.  This diversity is problematic as without 23 
comparability of outcomes across trials it is challenging to synthesize evidence effectively and draw 24 
the methodological conclusions necessary to inform decision-making for public health and improve 25 
the conduct of future trials.  This issue has become pressing in light of recent prominent 26 
disappointments in phase III studies and with the emerging need in the field to evaluate novel 27 
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combinations of drugs efficiently.[7] With this in mind, we systematically reviewed the literature of 1 
phase III studies in pulmonary TB to determine how outcomes are currently defined, and how 2 
commonly they are used in published studies to date. 3 
 4 
Methods 5 
The available literature was searched for randomised controlled trials, or quasi-randomised trials 6 
meeting the following inclusion criteria: trials including patients with  smear and culture positive 7 
pulmonary tuberculosis, trials including patients receiving treatment for the first time or with known 8 
isoniazid mono-resistant organisms on susceptibility testing, and including regimens containing any 9 
combination of the following drugs. Historic first-line treatment regimens with existing clinical data 10 
were included.  Additionally, any drugs with an active phase II clinical development programme were 11 
also included.  In particular trials including regimens containing any combination of ethambutol (E), 12 
gatifloxacin (G), isoniazid (H), bedaquiline (J), levofloxacin (L), moxifloxacin (M), ofloxacin (O), 13 
para-aminosalicylic acid (P), PA-824 (Pa), rifampicin (R), rifabutin (Rb), rifapentine (Rp), 14 
streptomycin (S), thiacetazone (T), and pyrazinamide (Z) were considered. There were no specific 15 
exclusion criteria in order to keep the review as broad as possible.  16 
PubMed, MEDLINE, EMBASE, CENTRAL and LILACs were searched on 30th November 2017 17 
using a defined inclusive search strategy as follows, without language restrictions.  No date 18 
restrictions were applied 19 
1. Tuberculosis and clinical trials 20 
2. Rifampicin or isoniazid or pyrazinamide or ethambutol or thiacetazone or para-aminosalicylic 21 
acid or streptomycin or rifabutin or rifapentine or levofloxacin or ofloxacin or gatifloxacin or 22 
moxifloxacin or bedaquiline or PA-824 23 
3. 1 & 2 24 
Hand searching of reference lists of included studies and relevant reviews was also undertaken to 25 
ensure all relevant studies were included.  Two authors (LB and GK-D) assessed all studies evaluating 26 
either monotherapy or combination regimens for inclusion. Phase III studies were identified on a case-27 
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by-case basis according to whether the study reported primary end of treatment or post-treatment 1 
outcomes at an appropriate sample size. Ambiguous cases and any disagreements were resolved by 2 
discussion with the third author (GD).  Two investigators (LB & GK-D) extracted the data using a 3 
piloted data extraction form. Data were summarised using appropriate graphical and numerical 4 
summaries in R (version 3.3.2).  In the case of multiple publications relating to a single study the 5 
publication with the largest number of reported outcomes was included as the main publication. The 6 
associated manuscripts were also checked for additional outcomes which were additionally reported 7 
as though they were part of the main publication. The protocol for this systematic review is available 8 
on request.  The review was not registered with PROSPERO.   9 
As a sensitivity analysis, we considered Venn diagrams for the reported outcomes in trials published 10 
before 1995 and from 1995 onwards.  This cut-off was chosen as representing the start of the modern 11 
era in TB clinical trials.   12 
 13 
Results 14 
Characteristics of included studies 15 
Figure 1 illustrates the flow of studies through the review.  The main reasons for exclusion were 16 
failure to meet the inclusion criteria, and study design other than randomised controlled trial. In total, 17 
248 relevant studies were identified and included. The included studies ranged in year of publication 18 
from 1950 until 2016 (Figure 2). Only 45 (18%) of the included studies were published after 1995. 19 
Hence the majority of included studies may not be expected to conform to the CONSORT guidelines 20 
on reporting of items such as trial design, intervention, participants, and outcomes.[8] 39 studies were 21 
reported in languages other than English. The most frequent alternative languages were Japanese (12 22 
studies), German (8 studies) and French (7 studies) with alternatives including Chinese, Italian, 23 
Danish, Russian, Dutch, Portuguese, Romanian and Polish. 24 
Figure 3 summarises the duration of treatment across studies and the extent of follow-up.  The most 25 
frequent treatment durations were 6 and 12 months.  Some studies only treated patients for 2 26 
months[9-11] while others tested treatment plans lasting 36 months.[12, 13] Follow-up after treatment 27 
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was completed was most frequently undertaken at 6, 12, 18, and 24 months.  The shortest duration of 1 
follow-up was 4 months[14] with some studies opting for 60 months of follow-up (e.g.[15-17]). 2 
During pilot data extraction, it was noted that definitions of treatment failure and relapse used in the 3 
reports were often inconsistently related to stage of treatment. For this reason, for the purposes of the 4 
review, outcomes were classified as “on-treatment” if treatment was continuing at the time of their 5 
evaluation, “off-treatment” if treatment had already been completed and “end of treatment” if they 6 
represented the final on-treatment evaluation. 7 
 8 
Definitions of outcomes 9 
There was wide variation in the definition and type of outcomes reported in the included studies. 10 
Nearly all reported multiple outcomes without any clear distinction between primary and secondary 11 
outcomes. Therefore all the outcomes included in each study were considered (n=1378), and are 12 
summarised in Additional file 1.  The most frequently reported outcomes were the proportion of 13 
participants experiencing a “relapse” (positive bacteriological tests in the “off-treatment” phase) (136 14 
out of 1378 reported outcomes, 10%), improvement or change in radiograph (n=100, 7%), and death 15 
from all or unspecified causes (n=90, 7%).  Adverse events were also frequently reported (n=179, 16 
13%).  17 
The reported outcomes can be broadly categorised into bacteriological (for example negative or 18 
positive mycobacterial cultures on various media), radiological (for example number of cavities seen 19 
on chest radiograph) and clinical (for example death), evaluated on or off treatment.  A Venn diagram 20 
summarising the number of trial reports including each of these categories of outcomes can be seen in 21 
Additional file 2; 27 studies reported only off-treatment outcomes while 106 studies reported only on-22 
treatment outcomes. The sensitivity analysis considering the reported outcomes in trials published 23 
before 1995 and from 1995 onwards can be seen in Additional file 3. It appears that in recent years 24 
trials have been less reliant on radiological results. 25 
 26 
Bacteriological outcomes 27 
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218 (82%) studies reported a bacteriological endpoint on treatment whilst 139 (52%) reported such an 1 
endpoint off treatment. There was a lack of consistency in whether sputum smear results were 2 
characterised as positive or negative and considerable variation in the time points at which relapse 3 
was assessed.  Cultures or smear status were more frequently reported as negative (102 of 1378 4 
reported outcomes, 7%) than positive (24, 2%). 5 
 Some studies considered “relapse” on treatment [18], while others considered it at various time points 6 
off treatment such as 12 [19], 18 [20], 24 [21], 36 [22], and 60 months.[17]  The definition of relapse 7 
also varied across studies, some considering relapse as defined by smear results [23], by both culture 8 
and smear results [23], or according to radiographic confirmation alone.[24]  In some modern trials, 9 
relapse was adjusted for molecular typing methods.[25]  Similar variability was observed among 10 
definitions of treatment failure.[23] Among bacteriological outcomes, the number of cultures obtained 11 
also varied from one culture at one time point (e.g. [26-28]) to multiple cultures at one time point, 12 
sometimes within one study (e.g. [29, 30]). Some studies adopted an intention to treat approach to 13 
analysis and included patients with missing or contaminated culture results, while others used a per 14 
protocol approach and excluded these patients. Poor quality reporting and high risk of bias meant it 15 
was mostly impossible to distinguish these situations.   16 
 17 
Death 18 
126 (51%) studies reported an outcome related to death (either on treatment, or off treatment). Death 19 
was classified in multiple ways ranging from all causes [31], through non-TB [32], to TB [33], 20 
assessed at a number of time points, and expressed as a variety of endpoints ranging from proportion 21 
to time to event.  53 (21%) of studies attempted to attribute cause of death to TB. 22 
 23 
Composite endpoints 24 
A subset of the included studies considered an explicitly composite endpoint of “unfavourable” as 25 
against “favourable”[34]. “Unfavourable” in modern trials characteristically included bacteriologically 26 
or clinically defined treatment failure or relapse [35], death from all causes (with the possible exception 27 
of trauma) while on treatment, death from TB in the off-treatment phase, failure to complete the 28 
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treatment regimen within a defined timeframe and/or withdrawal from the study before the end of 1 
treatment.[14] However, there were often potentially significant differences in the exact definition and 2 
implementation of the “unfavourable” outcome, even among the most recently conducted trials 3 
evaluating very similar treatment regimens.  4 
 5 
Conclusions 6 
Our systematic review identified considerable and potentially important variation among reported 7 
outcomes and their definitions among phase III trials of treatment for TB. These differences were 8 
apparent across a number of key dimensions and details. While the review necessarily reflects the 9 
evolution of clinical trials in TB over more than six decades, our findings have implications for the 10 
design and conduct of such studies in the future.  11 
It is possible that the definition of outcomes could be related to progress and trends within clinical 12 
guidelines in the pulmonary TB area (e.g. [36]). Such guidelines may have contributed to some 13 
changes in reported outcomes over time. However, the guidelines are focussed on programmatic 14 
treatment strategies and diagnostic methods rather than outcomes to be reported within clinical trials. 15 
Overall, studies were frequently hampered by the use of ambiguous or incompletely defined terms 16 
such as “treatment failure” and “relapse” which often appeared to embody unstated clinical or 17 
temporal assumptions. Over time, objective and usually blinded bacteriological assessments have 18 
been increasingly prioritised by TB trialists, particularly during the on-treatment phase while off-19 
treatment outcomes, although similarly based on bacteriology, often also have a clinical and/or a 20 
radiological dimension which is not always explicit.  In addition, the historical concept of “relapse” 21 
has been complicated by the recognition of reinfection enabled by novel molecular techniques. There 22 
was inconsistency in selection of the time points at which the outcomes were considered, the precise 23 
requirements for declaring bacteriological assessments negative or positive and in the total duration of 24 
off-treatment follow-up. While on-treatment outcomes would logically be reported as conversion to 25 
negative status and off-treatment outcomes as conversion to positive status, this distinction was not 26 
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consistently applied across trials.  In addition few trials clearly defined or reported per-protocol or 1 
intention-to-treat analysis populations or losses to follow-up. 2 
To avoid some of these problems, trialists have increasingly wished to explicitly combine several 3 
endpoints into a composite endpoint which better reflects the total performance of a treatment 4 
regimen over the entire course of treatment and follow-up and avoids the conditional linkage between 5 
on-treatment and off-treatment outcomes (absence of a poor on-treatment outcome being a 6 
precondition for off-treatment follow-up). Historically, these composite endpoints have been 7 
described as “favourable”/“unfavourable”. While this is a logical approach, in practice the scope of 8 
this composite endpoint may vary significantly, even between recent trials and the importance of 9 
some components can vary between trial settings, particularly mortality in study populations with a 10 
high rate of HIV seropositivity. Without closer harmonisation of such composite endpoints, it will 11 
remain important to continue to clearly report the disaggregated component outcomes as well as the 12 
composite in order to facilitate appropriate meta-analysis. 13 
In a prior systematic review of methodology in phase II studies in TB, we identified multiple 14 
competing approaches and analysis methods, which may be equally valid in an exploratory 15 
context.[37] Phase III outcomes however are confirmatory in nature and require broader consensus 16 
from both trialists and regulators.  This review suggests that simple measures could improve the 17 
quality of reporting of phase III studies and also highlights the need to develop a core outcome set for 18 
future pivotal trials in TB.  This would provide a set of clearly defined outcomes to be reported in 19 
each study,[38] but which would not be exhaustive giving trialists the freedom to report other 20 
outcomes of specific interest. The Core Outcome Measures in Effectiveness Trials (COMET) 21 
Initiative brings together people interested in the development and application of agreed standardised 22 
sets of outcomes. Thus our work is relevant in a broader setting than just trials within tuberculosis. 23 
Agreement on a meaningful core outcome set would make it easier for future trials to be compared, 24 
contrasted and combined in systematic reviews, ultimately facilitating understanding and accelerating 25 
improvement of treatment strategies for patients with TB.  This work is currently ongoing for phase II 26 
studies within TB following a recent systematic review of outcomes.[37] However, pending 27 
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development of, and agreement on, such a core outcome set, we suggest some interim 1 
recommendations for reporting of future phase III trials: 2 
Endpoints should be explicitly referred to in terms of their timing in relation to the end of treatment. 3 
Rather than the traditional and sometimes ambiguous terms “treatment failure” and “relapse”, 4 
bacteriological, clinical and/or radiological outcomes would be more clearly described as “on-5 
treatment” or “off-treatment”.  6 
Composite primary endpoints, for example, “unfavourable” or “favourable” should be clearly defined 7 
in trial reports and appropriately disaggregated into their components in relevant analyses.  8 
Reporting of bacteriological outcomes should clearly specify the definition of bacteriological 9 
conversion (whether negative or positive, including whether more than one time point is required and 10 
whether samples are to be replicated at each time point) and report the reasons for missing cultures 11 
(not obtained, contaminated).  While for phase II it seems most logical to report outcomes as 12 
conversion to culture negativity, for the purposes of reporting combined endpoints in phase III trials it 13 
is most consistent to report the positive on- and off-treatment outcomes together to avoid 14 
conditionality. 15 
Finally, where these recommendations cannot be met, availability of individual patient data could 16 
facilitate appropriate re-analysis and combination of similar outcomes wherever possible thus 17 
enabling and reducing heterogeneity in future meta-analyses. Improving the quality and interpretation 18 
of this evidence base will be critical in providing the best possible information on the equipoise and 19 
design of future clinical trials in TB.  20 
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Figure Legends 18 
Figure 1: Flow of studies in the review 19 
Figure 2: Year of publication of included studies 20 
Figure 3: Bar charts illustrating the number of included studies reporting each duration of treatment 21 
(left: blue bars) and also the duration of follow-up (right: green bars)  22 
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Additional File 1: Reported outcomes 25 
Additional File 2: Venn diagram summarising all reported outcomes. 26 
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Additional File 3: Venn diagrams summarising all reported outcomes according to the sensitivity 1 
analysis (i.e. pre- and post-CONSORT). 2 
